Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals, Inc. reports that Chief Scientific Officer Christian Heidbreder conducted an open-market sale of 18,586 shares of common stock at $41.14 per share on July 10, 2026. Following this transaction, he holds 209,337 shares directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
INDV submitted a Form 144 reporting 18,586 shares of Common stock tied to Restricted Stock Vesting dated 03/03/2026. The filing lists an aggregate value of $764,628.04 and shows a prior sale of 18,586 shares on 06/11/2026 with value $707,383.16.
Indivior Pharmaceuticals, Inc. reported that Chief Executive Officer Joseph Ciaffoni had performance stock units granted on May 13, 2025 vest at 100%, resulting in 1,266,903 common shares vesting on June 22, 2026. Each unit converted into one share of common stock. To cover related tax withholding obligations, 612,549 of these shares were withheld, and Ciaffoni now holds 790,330 shares of common stock directly. All 1,266,903 performance stock units were fully settled and no such units remain outstanding.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported an open-market sale of 18,586 shares of common stock at $38.06 per share. After this transaction on June 11, 2026, he directly holds 227,923 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026, indicating it was scheduled in advance rather than timed discretionarily.
Indivior Pharmaceuticals, Inc. reported that Chief Financial Officer Ryan Preblick sold 36,000 shares of Common Stock in an open-market transaction at $37.70 per share on June 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following this transaction, Preblick directly holds 284,751 shares, indicating he retains a substantial equity stake in the company.
INDV filed an amended Form 144 reporting intended dispositions totaling 36,000 shares through Fidelity Brokerage Services LLC on 06/08/2026. The filing lists three prior restricted stock vesting entries of 6,478, 6,247, and 23,275 shares dated 11/28/2021, 03/05/2022, and 03/09/2023, respectively. The document shows an aggregate value figure of $1,357,200.00 and references NASDAQ in the record.
INDV submitted a Form 144 notice listing the proposed sale of 36,000 shares of Common Stock. The filing shows an aggregate figure of $1,357,200.00 and a reference figure of 121,922,058 with the date 06/08/2026. The filing also lists prior restricted stock vesting entries of 6,478, 6,247 and 23,275 shares dated 11/28/2021, 03/05/2022 and 03/09/2023 respectively.
Indivior Pharmaceuticals, Inc. filed an update on management and shareholder voting. Effective June 1, 2026, the company will eliminate the Chief Scientific Officer role. Dr. Christian Heidbreder will move to an advisory role through the end of 2026, with his December 31, 2026 termination treated as a termination without cause under his employment agreement.
The filing also reports results of the May 13, 2026 virtual annual shareholder meeting. Stockholders elected eight directors, approved executive compensation on an advisory basis, chose an annual “say‑on‑pay” vote schedule, and ratified PricewaterhouseCoopers LLP US as independent auditor for the fiscal year ending December 31, 2026.
Madison Avenue International LP and affiliated reporting persons report beneficial ownership of 4,315,162 shares of Indivior Pharmaceuticals common stock as of March 31, 2026. The filing states this equals approximately 3.5% of the class based on 121,922,058 shares outstanding as of March 18, 2026.
The group structure disclosed names Madison Avenue Partners, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC, and Eli Samaha, each described with shared voting and dispositive power over the 4,315,162 shares.